nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ANKK1—nicotine dependence	0.78	1	CbGaD
Crizotinib—Vitreous floaters—Varenicline—nicotine dependence	0.00949	0.18	CcSEcCtD
Crizotinib—Balance disorder—Varenicline—nicotine dependence	0.00394	0.0749	CcSEcCtD
Crizotinib—NEK9—cardiovascular system—nicotine dependence	0.00243	0.0215	CbGeAlD
Crizotinib—ROS1—brain—nicotine dependence	0.0024	0.0212	CbGeAlD
Crizotinib—PRKD1—cardiovascular system—nicotine dependence	0.00222	0.0196	CbGeAlD
Crizotinib—EPHA7—brain—nicotine dependence	0.0022	0.0194	CbGeAlD
Crizotinib—Pulmonary embolism—Varenicline—nicotine dependence	0.00215	0.041	CcSEcCtD
Crizotinib—Photophobia—Varenicline—nicotine dependence	0.00202	0.0385	CcSEcCtD
Crizotinib—NTRK1—midbrain—nicotine dependence	0.00201	0.0178	CbGeAlD
Crizotinib—MAPK7—cardiovascular system—nicotine dependence	0.00197	0.0174	CbGeAlD
Crizotinib—MET—cardiovascular system—nicotine dependence	0.00184	0.0163	CbGeAlD
Crizotinib—LIMK1—midbrain—nicotine dependence	0.00171	0.0151	CbGeAlD
Crizotinib—Visual disturbance—Varenicline—nicotine dependence	0.00165	0.0314	CcSEcCtD
Crizotinib—DSTYK—midbrain—nicotine dependence	0.00162	0.0144	CbGeAlD
Crizotinib—IGF1R—cardiovascular system—nicotine dependence	0.00145	0.0128	CbGeAlD
Crizotinib—Hypokalaemia—Varenicline—nicotine dependence	0.00142	0.0271	CcSEcCtD
Crizotinib—TIE1—cardiovascular system—nicotine dependence	0.00141	0.0125	CbGeAlD
Crizotinib—ACVR1—cardiovascular system—nicotine dependence	0.00128	0.0113	CbGeAlD
Crizotinib—FLT3—cardiovascular system—nicotine dependence	0.00128	0.0113	CbGeAlD
Crizotinib—DCLK1—midbrain—nicotine dependence	0.00126	0.0112	CbGeAlD
Crizotinib—Infestation—Varenicline—nicotine dependence	0.0012	0.0229	CcSEcCtD
Crizotinib—Infestation NOS—Varenicline—nicotine dependence	0.0012	0.0229	CcSEcCtD
Crizotinib—NEK9—brain—nicotine dependence	0.00119	0.0106	CbGeAlD
Crizotinib—FER—midbrain—nicotine dependence	0.00118	0.0104	CbGeAlD
Crizotinib—EPHA5—midbrain—nicotine dependence	0.00118	0.0104	CbGeAlD
Crizotinib—ALK—midbrain—nicotine dependence	0.00118	0.0104	CbGeAlD
Crizotinib—PTK2B—cardiovascular system—nicotine dependence	0.00117	0.0103	CbGeAlD
Crizotinib—RIPK2—cardiovascular system—nicotine dependence	0.00116	0.0102	CbGeAlD
Crizotinib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00114	0.0217	CcSEcCtD
Crizotinib—MAP4K2—midbrain—nicotine dependence	0.00111	0.00986	CbGeAlD
Crizotinib—Bradycardia—Varenicline—nicotine dependence	0.0011	0.0209	CcSEcCtD
Crizotinib—PRKD1—brain—nicotine dependence	0.00109	0.00962	CbGeAlD
Crizotinib—Hypoaesthesia—Varenicline—nicotine dependence	0.00108	0.0205	CcSEcCtD
Crizotinib—PTK2—cardiovascular system—nicotine dependence	0.00107	0.00951	CbGeAlD
Crizotinib—TBK1—cardiovascular system—nicotine dependence	0.00107	0.00951	CbGeAlD
Crizotinib—SIK2—brain—nicotine dependence	0.00107	0.00949	CbGeAlD
Crizotinib—LIMK1—brain—nicotine dependence	0.00107	0.00949	CbGeAlD
Crizotinib—Urinary tract disorder—Varenicline—nicotine dependence	0.00107	0.0203	CcSEcCtD
Crizotinib—TYK2—cardiovascular system—nicotine dependence	0.00107	0.00944	CbGeAlD
Crizotinib—Oedema peripheral—Varenicline—nicotine dependence	0.00107	0.0203	CcSEcCtD
Crizotinib—TESK1—midbrain—nicotine dependence	0.00106	0.0094	CbGeAlD
Crizotinib—Urethral disorder—Varenicline—nicotine dependence	0.00106	0.0202	CcSEcCtD
Crizotinib—PRKD3—brain—nicotine dependence	0.00105	0.00925	CbGeAlD
Crizotinib—Visual impairment—Varenicline—nicotine dependence	0.00104	0.0198	CcSEcCtD
Crizotinib—RPS6KB1—cardiovascular system—nicotine dependence	0.00103	0.00914	CbGeAlD
Crizotinib—FGR—cardiovascular system—nicotine dependence	0.00103	0.00909	CbGeAlD
Crizotinib—AXL—cardiovascular system—nicotine dependence	0.00102	0.00905	CbGeAlD
Crizotinib—DSTYK—brain—nicotine dependence	0.00102	0.00902	CbGeAlD
Crizotinib—Eye disorder—Varenicline—nicotine dependence	0.00101	0.0192	CcSEcCtD
Crizotinib—Cardiac disorder—Varenicline—nicotine dependence	0.001	0.0191	CcSEcCtD
Crizotinib—MAP3K12—midbrain—nicotine dependence	0.001	0.00885	CbGeAlD
Crizotinib—ACVR1—midbrain—nicotine dependence	0.001	0.00885	CbGeAlD
Crizotinib—LTK—brain—nicotine dependence	0.000997	0.00882	CbGeAlD
Crizotinib—CASK—brain—nicotine dependence	0.000997	0.00882	CbGeAlD
Crizotinib—STK35—midbrain—nicotine dependence	0.00098	0.00867	CbGeAlD
Crizotinib—EPHB4—cardiovascular system—nicotine dependence	0.000978	0.00865	CbGeAlD
Crizotinib—Mediastinal disorder—Varenicline—nicotine dependence	0.000975	0.0185	CcSEcCtD
Crizotinib—JAK2—cardiovascular system—nicotine dependence	0.000971	0.00859	CbGeAlD
Crizotinib—Arrhythmia—Varenicline—nicotine dependence	0.000966	0.0184	CcSEcCtD
Crizotinib—MAPK7—brain—nicotine dependence	0.000966	0.00854	CbGeAlD
Crizotinib—EPHA2—cardiovascular system—nicotine dependence	0.000959	0.00849	CbGeAlD
Crizotinib—FES—brain—nicotine dependence	0.000956	0.00846	CbGeAlD
Crizotinib—EPHA8—brain—nicotine dependence	0.000956	0.00846	CbGeAlD
Crizotinib—BMP2K—midbrain—nicotine dependence	0.000944	0.00835	CbGeAlD
Crizotinib—Malnutrition—Varenicline—nicotine dependence	0.000941	0.0179	CcSEcCtD
Crizotinib—MAP3K3—cardiovascular system—nicotine dependence	0.000936	0.00828	CbGeAlD
Crizotinib—TEK—cardiovascular system—nicotine dependence	0.000936	0.00828	CbGeAlD
Crizotinib—Dysgeusia—Varenicline—nicotine dependence	0.000922	0.0175	CcSEcCtD
Crizotinib—MET—brain—nicotine dependence	0.000904	0.008	CbGeAlD
Crizotinib—RIPK2—midbrain—nicotine dependence	0.000904	0.008	CbGeAlD
Crizotinib—Vision blurred—Varenicline—nicotine dependence	0.000887	0.0169	CcSEcCtD
Crizotinib—CDK7—brain—nicotine dependence	0.000874	0.00773	CbGeAlD
Crizotinib—Anaemia—Varenicline—nicotine dependence	0.00087	0.0165	CcSEcCtD
Crizotinib—TAOK2—brain—nicotine dependence	0.000867	0.00767	CbGeAlD
Crizotinib—STK10—cardiovascular system—nicotine dependence	0.000857	0.00758	CbGeAlD
Crizotinib—TAOK3—cardiovascular system—nicotine dependence	0.000853	0.00755	CbGeAlD
Crizotinib—Syncope—Varenicline—nicotine dependence	0.000844	0.0161	CcSEcCtD
Crizotinib—PTK2—midbrain—nicotine dependence	0.000839	0.00742	CbGeAlD
Crizotinib—TBK1—midbrain—nicotine dependence	0.000839	0.00742	CbGeAlD
Crizotinib—EPHA3—brain—nicotine dependence	0.000836	0.00739	CbGeAlD
Crizotinib—ACVR1B—brain—nicotine dependence	0.000836	0.00739	CbGeAlD
Crizotinib—TYK2—midbrain—nicotine dependence	0.000834	0.00737	CbGeAlD
Crizotinib—SRC—cardiovascular system—nicotine dependence	0.000832	0.00736	CbGeAlD
Crizotinib—Loss of consciousness—Varenicline—nicotine dependence	0.000827	0.0157	CcSEcCtD
Crizotinib—IRAK1—midbrain—nicotine dependence	0.000823	0.00728	CbGeAlD
Crizotinib—RPS6KB1—midbrain—nicotine dependence	0.000807	0.00714	CbGeAlD
Crizotinib—AXL—midbrain—nicotine dependence	0.000799	0.00707	CbGeAlD
Crizotinib—JAK3—brain—nicotine dependence	0.000797	0.00705	CbGeAlD
Crizotinib—EPHA6—brain—nicotine dependence	0.000797	0.00705	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000796	0.0151	CcSEcCtD
Crizotinib—DCLK1—brain—nicotine dependence	0.000792	0.00701	CbGeAlD
Crizotinib—PLK4—brain—nicotine dependence	0.000787	0.00696	CbGeAlD
Crizotinib—STK4—brain—nicotine dependence	0.000782	0.00692	CbGeAlD
Crizotinib—SLK—midbrain—nicotine dependence	0.000769	0.00681	CbGeAlD
Crizotinib—Oedema—Varenicline—nicotine dependence	0.000768	0.0146	CcSEcCtD
Crizotinib—EPHB4—midbrain—nicotine dependence	0.000764	0.00676	CbGeAlD
Crizotinib—Infection—Varenicline—nicotine dependence	0.000763	0.0145	CcSEcCtD
Crizotinib—Shock—Varenicline—nicotine dependence	0.000756	0.0144	CcSEcCtD
Crizotinib—Nervous system disorder—Varenicline—nicotine dependence	0.000753	0.0143	CcSEcCtD
Crizotinib—CSF1R—cardiovascular system—nicotine dependence	0.000747	0.0066	CbGeAlD
Crizotinib—Skin disorder—Varenicline—nicotine dependence	0.000746	0.0142	CcSEcCtD
Crizotinib—FER—brain—nicotine dependence	0.00074	0.00654	CbGeAlD
Crizotinib—TYRO3—brain—nicotine dependence	0.00074	0.00654	CbGeAlD
Crizotinib—EPHA5—brain—nicotine dependence	0.00074	0.00654	CbGeAlD
Crizotinib—ALK—brain—nicotine dependence	0.00074	0.00654	CbGeAlD
Crizotinib—LYN—brain—nicotine dependence	0.000736	0.00651	CbGeAlD
Crizotinib—TNK1—brain—nicotine dependence	0.000732	0.00647	CbGeAlD
Crizotinib—MAP3K3—midbrain—nicotine dependence	0.000731	0.00647	CbGeAlD
Crizotinib—MAP4K5—midbrain—nicotine dependence	0.000731	0.00647	CbGeAlD
Crizotinib—TEK—midbrain—nicotine dependence	0.000731	0.00647	CbGeAlD
Crizotinib—MAP4K1—brain—nicotine dependence	0.000724	0.00641	CbGeAlD
Crizotinib—MAP3K19—brain—nicotine dependence	0.000724	0.00641	CbGeAlD
Crizotinib—BMPR1B—brain—nicotine dependence	0.000724	0.00641	CbGeAlD
Crizotinib—TNK2—brain—nicotine dependence	0.00071	0.00629	CbGeAlD
Crizotinib—IGF1R—brain—nicotine dependence	0.00071	0.00629	CbGeAlD
Crizotinib—MAP4K2—brain—nicotine dependence	0.000701	0.0062	CbGeAlD
Crizotinib—EPHB6—midbrain—nicotine dependence	0.000699	0.00618	CbGeAlD
Crizotinib—TIE1—brain—nicotine dependence	0.000691	0.00611	CbGeAlD
Crizotinib—STK3—brain—nicotine dependence	0.000691	0.00611	CbGeAlD
Crizotinib—Dyspnoea—Varenicline—nicotine dependence	0.000685	0.013	CcSEcCtD
Crizotinib—Dyspepsia—Varenicline—nicotine dependence	0.000676	0.0129	CcSEcCtD
Crizotinib—YES1—midbrain—nicotine dependence	0.000675	0.00597	CbGeAlD
Crizotinib—AURKA—brain—nicotine dependence	0.000674	0.00596	CbGeAlD
Crizotinib—TESK1—brain—nicotine dependence	0.000668	0.00591	CbGeAlD
Crizotinib—Decreased appetite—Varenicline—nicotine dependence	0.000668	0.0127	CcSEcCtD
Crizotinib—TAOK3—midbrain—nicotine dependence	0.000666	0.0059	CbGeAlD
Crizotinib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000663	0.0126	CcSEcCtD
Crizotinib—Fatigue—Varenicline—nicotine dependence	0.000662	0.0126	CcSEcCtD
Crizotinib—Constipation—Varenicline—nicotine dependence	0.000657	0.0125	CcSEcCtD
Crizotinib—MERTK—brain—nicotine dependence	0.00065	0.00575	CbGeAlD
Crizotinib—LIMK2—brain—nicotine dependence	0.000636	0.00562	CbGeAlD
Crizotinib—NUAK2—brain—nicotine dependence	0.000633	0.0056	CbGeAlD
Crizotinib—MAP3K12—brain—nicotine dependence	0.000629	0.00556	CbGeAlD
Crizotinib—ACVR1—brain—nicotine dependence	0.000629	0.00556	CbGeAlD
Crizotinib—STK35—brain—nicotine dependence	0.000616	0.00545	CbGeAlD
Crizotinib—Body temperature increased—Varenicline—nicotine dependence	0.000607	0.0116	CcSEcCtD
Crizotinib—ABL2—brain—nicotine dependence	0.0006	0.00531	CbGeAlD
Crizotinib—BMP2K—brain—nicotine dependence	0.000593	0.00525	CbGeAlD
Crizotinib—ABL1—cardiovascular system—nicotine dependence	0.00059	0.00522	CbGeAlD
Crizotinib—CSF1R—midbrain—nicotine dependence	0.000583	0.00516	CbGeAlD
Crizotinib—PTK2B—brain—nicotine dependence	0.000573	0.00507	CbGeAlD
Crizotinib—RIPK2—brain—nicotine dependence	0.000568	0.00502	CbGeAlD
Crizotinib—Asthenia—Varenicline—nicotine dependence	0.000551	0.0105	CcSEcCtD
Crizotinib—EPHA4—brain—nicotine dependence	0.000549	0.00486	CbGeAlD
Crizotinib—MAP3K2—brain—nicotine dependence	0.000538	0.00476	CbGeAlD
Crizotinib—TBK1—brain—nicotine dependence	0.000527	0.00466	CbGeAlD
Crizotinib—PTK2—brain—nicotine dependence	0.000527	0.00466	CbGeAlD
Crizotinib—Diarrhoea—Varenicline—nicotine dependence	0.000526	0.01	CcSEcCtD
Crizotinib—TYK2—brain—nicotine dependence	0.000524	0.00463	CbGeAlD
Crizotinib—IRAK1—brain—nicotine dependence	0.000517	0.00457	CbGeAlD
Crizotinib—Dizziness—Varenicline—nicotine dependence	0.000508	0.00966	CcSEcCtD
Crizotinib—RPS6KB1—brain—nicotine dependence	0.000507	0.00449	CbGeAlD
Crizotinib—FGR—brain—nicotine dependence	0.000504	0.00446	CbGeAlD
Crizotinib—AXL—brain—nicotine dependence	0.000502	0.00444	CbGeAlD
Crizotinib—Vomiting—Varenicline—nicotine dependence	0.000488	0.00929	CcSEcCtD
Crizotinib—Rash—Varenicline—nicotine dependence	0.000484	0.00921	CcSEcCtD
Crizotinib—Dermatitis—Varenicline—nicotine dependence	0.000484	0.0092	CcSEcCtD
Crizotinib—SLK—brain—nicotine dependence	0.000483	0.00428	CbGeAlD
Crizotinib—EPHB4—brain—nicotine dependence	0.00048	0.00425	CbGeAlD
Crizotinib—JAK2—brain—nicotine dependence	0.000477	0.00422	CbGeAlD
Crizotinib—EPHA2—brain—nicotine dependence	0.000471	0.00416	CbGeAlD
Crizotinib—ABL1—midbrain—nicotine dependence	0.000461	0.00408	CbGeAlD
Crizotinib—MAP4K5—brain—nicotine dependence	0.000459	0.00406	CbGeAlD
Crizotinib—TEK—brain—nicotine dependence	0.000459	0.00406	CbGeAlD
Crizotinib—MAP3K3—brain—nicotine dependence	0.000459	0.00406	CbGeAlD
Crizotinib—Nausea—Varenicline—nicotine dependence	0.000456	0.00868	CcSEcCtD
Crizotinib—EPHB6—brain—nicotine dependence	0.000439	0.00388	CbGeAlD
Crizotinib—YES1—brain—nicotine dependence	0.000424	0.00375	CbGeAlD
Crizotinib—STK10—brain—nicotine dependence	0.00042	0.00372	CbGeAlD
Crizotinib—TAOK3—brain—nicotine dependence	0.000419	0.0037	CbGeAlD
Crizotinib—SRC—brain—nicotine dependence	0.000408	0.00361	CbGeAlD
Crizotinib—CSF1R—brain—nicotine dependence	0.000366	0.00324	CbGeAlD
Crizotinib—ABL1—brain—nicotine dependence	0.00029	0.00256	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—nicotine dependence	0.000184	0.00162	CbGeAlD
Crizotinib—ACVR1B—Signaling Pathways—FGD1—nicotine dependence	0.000145	0.00266	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—DRD2—nicotine dependence	0.000145	0.00265	CbGpPWpGaD
Crizotinib—ABCB1—midbrain—nicotine dependence	0.000143	0.00127	CbGeAlD
Crizotinib—PRKD1—Metabolism—CYP2A7—nicotine dependence	0.000142	0.00261	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—FGD1—nicotine dependence	0.000141	0.00258	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TAS2R16—nicotine dependence	0.00014	0.00256	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—FGD1—nicotine dependence	0.000137	0.00252	CbGpPWpGaD
Crizotinib—TXK—Immune System—WASF2—nicotine dependence	0.000136	0.00249	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—FGD1—nicotine dependence	0.000134	0.00245	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—CCAR1—nicotine dependence	0.000131	0.00241	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—WASF2—nicotine dependence	0.000131	0.0024	CbGpPWpGaD
Crizotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00013	0.00239	CbGpPWpGaD
Crizotinib—TXK—Immune System—WASF1—nicotine dependence	0.00013	0.00238	CbGpPWpGaD
Crizotinib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000128	0.00236	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000128	0.00235	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—AKR1B10—nicotine dependence	0.000128	0.00235	CbGpPWpGaD
Crizotinib—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000128	0.00235	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—WASF2—nicotine dependence	0.000127	0.00232	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TAS2R16—nicotine dependence	0.000127	0.00232	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—WASF1—nicotine dependence	0.000126	0.00231	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—FGD1—nicotine dependence	0.000126	0.0023	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—FGD1—nicotine dependence	0.000125	0.00229	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TAS2R16—nicotine dependence	0.000124	0.00227	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—FGD1—nicotine dependence	0.000121	0.00223	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—AKR1B10—nicotine dependence	0.000121	0.00222	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—WASF1—nicotine dependence	0.000121	0.00222	CbGpPWpGaD
Crizotinib—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000121	0.00221	CbGpPWpGaD
Crizotinib—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000119	0.00218	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000111	0.00203	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—FGD1—nicotine dependence	0.00011	0.00201	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—OPRM1—nicotine dependence	0.000109	0.002	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—WASF2—nicotine dependence	0.000108	0.00197	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—WASF2—nicotine dependence	0.000106	0.00194	CbGpPWpGaD
Crizotinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000106	0.00193	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—WASF1—nicotine dependence	0.000103	0.00189	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—WASF2—nicotine dependence	0.000103	0.00188	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—WASF2—nicotine dependence	0.000101	0.00186	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—WASF1—nicotine dependence	0.000101	0.00186	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—FGD1—nicotine dependence	9.93e-05	0.00182	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—WASF1—nicotine dependence	9.85e-05	0.00181	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—TAS2R16—nicotine dependence	9.83e-05	0.0018	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—WASF1—nicotine dependence	9.72e-05	0.00178	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—FGD1—nicotine dependence	9.72e-05	0.00178	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKR1B10—nicotine dependence	9.7e-05	0.00178	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—WASF2—nicotine dependence	9.35e-05	0.00171	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—WASF2—nicotine dependence	9.35e-05	0.00171	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—OPRM1—nicotine dependence	9.29e-05	0.0017	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TAS2R16—nicotine dependence	9.15e-05	0.00168	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—WASF2—nicotine dependence	9.01e-05	0.00165	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—WASF2—nicotine dependence	9.01e-05	0.00165	CbGpPWpGaD
Crizotinib—ABCB1—brain—nicotine dependence	9.01e-05	0.000797	CbGeAlD
Crizotinib—MAPK7—Immune System—WASF1—nicotine dependence	8.97e-05	0.00164	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—WASF1—nicotine dependence	8.97e-05	0.00164	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—OPRM1—nicotine dependence	8.84e-05	0.00162	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKR1B10—nicotine dependence	8.77e-05	0.00161	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—WASF1—nicotine dependence	8.64e-05	0.00158	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—WASF1—nicotine dependence	8.64e-05	0.00158	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKR1B10—nicotine dependence	8.58e-05	0.00157	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—WASF2—nicotine dependence	8.55e-05	0.00157	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKR1B10—nicotine dependence	8.46e-05	0.00155	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—WASF2—nicotine dependence	8.3e-05	0.00152	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—TAS2R16—nicotine dependence	8.21e-05	0.0015	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—WASF1—nicotine dependence	8.19e-05	0.0015	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—WASF2—nicotine dependence	8.18e-05	0.0015	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TAS2R16—nicotine dependence	8.15e-05	0.00149	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TAS2R16—nicotine dependence	8.03e-05	0.00147	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—WASF1—nicotine dependence	7.95e-05	0.00146	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—DRD2—nicotine dependence	7.9e-05	0.00145	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—WASF1—nicotine dependence	7.84e-05	0.00144	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—WASF2—nicotine dependence	7.82e-05	0.00143	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—OPRM1—nicotine dependence	7.78e-05	0.00143	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—OPRM1—nicotine dependence	7.78e-05	0.00143	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—WASF2—nicotine dependence	7.76e-05	0.00142	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—FGD1—nicotine dependence	7.72e-05	0.00141	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TAS2R16—nicotine dependence	7.69e-05	0.00141	CbGpPWpGaD
Crizotinib—TBK1—Immune System—WASF2—nicotine dependence	7.64e-05	0.0014	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—WASF2—nicotine dependence	7.53e-05	0.00138	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—WASF1—nicotine dependence	7.49e-05	0.00137	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TAS2R16—nicotine dependence	7.46e-05	0.00137	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—TAS2R16—nicotine dependence	7.45e-05	0.00137	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—WASF1—nicotine dependence	7.44e-05	0.00136	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—OPRM1—nicotine dependence	7.38e-05	0.00135	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—WASF2—nicotine dependence	7.32e-05	0.00134	CbGpPWpGaD
Crizotinib—TBK1—Immune System—WASF1—nicotine dependence	7.32e-05	0.00134	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—WASF1—nicotine dependence	7.22e-05	0.00132	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—OPRM1—nicotine dependence	7.19e-05	0.00132	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGD1—nicotine dependence	7.18e-05	0.00132	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—WASF1—nicotine dependence	7.02e-05	0.00129	CbGpPWpGaD
Crizotinib—JAK3—Immune System—WASF2—nicotine dependence	6.91e-05	0.00127	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—WASF2—nicotine dependence	6.83e-05	0.00125	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—OPRM1—nicotine dependence	6.75e-05	0.00124	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—DRD2—nicotine dependence	6.71e-05	0.00123	CbGpPWpGaD
Crizotinib—JAK3—Immune System—WASF1—nicotine dependence	6.62e-05	0.00121	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—WASF1—nicotine dependence	6.55e-05	0.0012	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—OPRM1—nicotine dependence	6.53e-05	0.0012	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—FGD1—nicotine dependence	6.44e-05	0.00118	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TAS2R16—nicotine dependence	6.4e-05	0.00117	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGD1—nicotine dependence	6.4e-05	0.00117	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—DRD2—nicotine dependence	6.39e-05	0.00117	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKR1B10—nicotine dependence	6.34e-05	0.00116	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TAS2R16—nicotine dependence	6.31e-05	0.00116	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGD1—nicotine dependence	6.3e-05	0.00116	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—WASF2—nicotine dependence	6.18e-05	0.00113	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—WASF2—nicotine dependence	6.16e-05	0.00113	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—WASF2—nicotine dependence	6.1e-05	0.00112	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—WASF2—nicotine dependence	6.07e-05	0.00111	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—WASF2—nicotine dependence	6.07e-05	0.00111	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—WASF2—nicotine dependence	6.05e-05	0.00111	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGD1—nicotine dependence	6.03e-05	0.00111	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TAS2R16—nicotine dependence	5.98e-05	0.0011	CbGpPWpGaD
Crizotinib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	5.95e-05	0.00109	CbGpPWpGaD
Crizotinib—BLK—Immune System—WASF2—nicotine dependence	5.92e-05	0.00109	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—WASF1—nicotine dependence	5.92e-05	0.00109	CbGpPWpGaD
Crizotinib—FGR—Immune System—WASF2—nicotine dependence	5.9e-05	0.00108	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—WASF1—nicotine dependence	5.9e-05	0.00108	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—OPRM1—nicotine dependence	5.9e-05	0.00108	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGD1—nicotine dependence	5.85e-05	0.00107	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—WASF1—nicotine dependence	5.85e-05	0.00107	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—FGD1—nicotine dependence	5.85e-05	0.00107	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—WASF1—nicotine dependence	5.82e-05	0.00107	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—WASF1—nicotine dependence	5.82e-05	0.00107	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TAS2R16—nicotine dependence	5.81e-05	0.00106	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—WASF1—nicotine dependence	5.8e-05	0.00106	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKR1B10—nicotine dependence	5.75e-05	0.00105	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—WASF2—nicotine dependence	5.71e-05	0.00105	CbGpPWpGaD
Crizotinib—BLK—Immune System—WASF1—nicotine dependence	5.68e-05	0.00104	CbGpPWpGaD
Crizotinib—FGR—Immune System—WASF1—nicotine dependence	5.66e-05	0.00104	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKR1B10—nicotine dependence	5.65e-05	0.00104	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—DRD2—nicotine dependence	5.63e-05	0.00103	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—DRD2—nicotine dependence	5.63e-05	0.00103	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	5.61e-05	0.00103	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKR1B10—nicotine dependence	5.57e-05	0.00102	CbGpPWpGaD
Crizotinib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	5.53e-05	0.00101	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—WASF1—nicotine dependence	5.47e-05	0.001	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—DRD2—nicotine dependence	5.33e-05	0.000978	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—OPRM1—nicotine dependence	5.33e-05	0.000978	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKR1B10—nicotine dependence	5.33e-05	0.000977	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—OPRM1—nicotine dependence	5.22e-05	0.000957	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—DRD2—nicotine dependence	5.2e-05	0.000953	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKR1B10—nicotine dependence	5.17e-05	0.000947	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGD1—nicotine dependence	5.02e-05	0.00092	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—WASF2—nicotine dependence	5e-05	0.000917	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGD1—nicotine dependence	4.95e-05	0.000907	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—DRD2—nicotine dependence	4.88e-05	0.000894	CbGpPWpGaD
Crizotinib—PTK2—Immune System—WASF2—nicotine dependence	4.83e-05	0.000886	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—WASF1—nicotine dependence	4.79e-05	0.000879	CbGpPWpGaD
Crizotinib—YES1—Immune System—WASF2—nicotine dependence	4.77e-05	0.000874	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—DRD2—nicotine dependence	4.72e-05	0.000865	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TAS2R16—nicotine dependence	4.7e-05	0.000862	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGD1—nicotine dependence	4.7e-05	0.000861	CbGpPWpGaD
Crizotinib—PTK2—Immune System—WASF1—nicotine dependence	4.63e-05	0.000849	CbGpPWpGaD
Crizotinib—YES1—Immune System—WASF1—nicotine dependence	4.57e-05	0.000837	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGD1—nicotine dependence	4.56e-05	0.000836	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—WASF2—nicotine dependence	4.52e-05	0.000828	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—WASF2—nicotine dependence	4.47e-05	0.000819	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKR1B10—nicotine dependence	4.43e-05	0.000813	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—WASF2—nicotine dependence	4.43e-05	0.000811	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TAS2R16—nicotine dependence	4.4e-05	0.000807	CbGpPWpGaD
Crizotinib—TYK2—Immune System—WASF2—nicotine dependence	4.39e-05	0.000804	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKR1B10—nicotine dependence	4.37e-05	0.000802	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKR1B10—nicotine dependence	4.36e-05	0.000799	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—WASF1—nicotine dependence	4.33e-05	0.000794	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—WASF1—nicotine dependence	4.28e-05	0.000785	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—DRD2—nicotine dependence	4.26e-05	0.000782	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—WASF1—nicotine dependence	4.24e-05	0.000778	CbGpPWpGaD
Crizotinib—TYK2—Immune System—WASF1—nicotine dependence	4.21e-05	0.000771	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKR1B10—nicotine dependence	4.15e-05	0.00076	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—OPRM1—nicotine dependence	4.15e-05	0.00076	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKR1B10—nicotine dependence	4.03e-05	0.000738	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—WASF2—nicotine dependence	3.98e-05	0.00073	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—WASF2—nicotine dependence	3.92e-05	0.000719	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TAS2R16—nicotine dependence	3.86e-05	0.000707	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—OPRM1—nicotine dependence	3.86e-05	0.000707	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—DRD2—nicotine dependence	3.86e-05	0.000707	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—WASF1—nicotine dependence	3.82e-05	0.0007	CbGpPWpGaD
Crizotinib—LCK—Disease—AKR1B10—nicotine dependence	3.82e-05	0.0007	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—DRD2—nicotine dependence	3.77e-05	0.000692	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—WASF1—nicotine dependence	3.76e-05	0.00069	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—WASF2—nicotine dependence	3.76e-05	0.000688	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGD1—nicotine dependence	3.69e-05	0.000677	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—WASF2—nicotine dependence	3.64e-05	0.000667	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—WASF1—nicotine dependence	3.6e-05	0.00066	CbGpPWpGaD
Crizotinib—LYN—Immune System—WASF2—nicotine dependence	3.55e-05	0.000651	CbGpPWpGaD
Crizotinib—ABL1—Immune System—WASF2—nicotine dependence	3.54e-05	0.000648	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—WASF1—nicotine dependence	3.49e-05	0.00064	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—OPRM1—nicotine dependence	3.46e-05	0.000634	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGD1—nicotine dependence	3.45e-05	0.000633	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—OPRM1—nicotine dependence	3.44e-05	0.00063	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TAS2R16—nicotine dependence	3.41e-05	0.000626	CbGpPWpGaD
Crizotinib—LYN—Immune System—WASF1—nicotine dependence	3.41e-05	0.000624	CbGpPWpGaD
Crizotinib—ABL1—Immune System—WASF1—nicotine dependence	3.39e-05	0.000622	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—OPRM1—nicotine dependence	3.39e-05	0.000621	CbGpPWpGaD
Crizotinib—SRC—Disease—AKR1B10—nicotine dependence	3.38e-05	0.000619	CbGpPWpGaD
Crizotinib—JAK2—Immune System—WASF2—nicotine dependence	3.33e-05	0.00061	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	3.32e-05	0.000609	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKR1B10—nicotine dependence	3.26e-05	0.000598	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—OPRM1—nicotine dependence	3.24e-05	0.000594	CbGpPWpGaD
Crizotinib—JAK2—Immune System—WASF1—nicotine dependence	3.19e-05	0.000584	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—OPRM1—nicotine dependence	3.14e-05	0.000576	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—OPRM1—nicotine dependence	3.14e-05	0.000576	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—WASF2—nicotine dependence	3.12e-05	0.000573	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—WASF2—nicotine dependence	3.08e-05	0.000565	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKR1B10—nicotine dependence	3.05e-05	0.000559	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGD1—nicotine dependence	3.03e-05	0.000555	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD2—nicotine dependence	3e-05	0.000549	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—WASF1—nicotine dependence	3e-05	0.000549	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—WASF1—nicotine dependence	2.95e-05	0.000541	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—WASF2—nicotine dependence	2.92e-05	0.000536	CbGpPWpGaD
Crizotinib—LCK—Immune System—WASF2—nicotine dependence	2.91e-05	0.000534	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—WASF2—nicotine dependence	2.84e-05	0.00052	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—WASF1—nicotine dependence	2.8e-05	0.000514	CbGpPWpGaD
Crizotinib—LCK—Immune System—WASF1—nicotine dependence	2.79e-05	0.000512	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD2—nicotine dependence	2.79e-05	0.000511	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—WASF1—nicotine dependence	2.72e-05	0.000499	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—OPRM1—nicotine dependence	2.7e-05	0.000494	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGD1—nicotine dependence	2.68e-05	0.000491	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKR1B10—nicotine dependence	2.67e-05	0.00049	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—OPRM1—nicotine dependence	2.66e-05	0.000488	CbGpPWpGaD
Crizotinib—SRC—Immune System—WASF2—nicotine dependence	2.58e-05	0.000473	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—OPRM1—nicotine dependence	2.52e-05	0.000462	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD2—nicotine dependence	2.5e-05	0.000458	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD2—nicotine dependence	2.48e-05	0.000455	CbGpPWpGaD
Crizotinib—SRC—Immune System—WASF1—nicotine dependence	2.47e-05	0.000453	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—OPRM1—nicotine dependence	2.45e-05	0.000449	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD2—nicotine dependence	2.45e-05	0.000449	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKR1B10—nicotine dependence	2.37e-05	0.000434	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD2—nicotine dependence	2.34e-05	0.00043	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—WASF2—nicotine dependence	2.3e-05	0.000421	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD2—nicotine dependence	2.27e-05	0.000417	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD2—nicotine dependence	2.27e-05	0.000416	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—WASF1—nicotine dependence	2.2e-05	0.000404	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—WASF2—nicotine dependence	2.15e-05	0.000394	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP2A7—nicotine dependence	2.06e-05	0.000378	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—WASF1—nicotine dependence	2.06e-05	0.000378	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—OPRM1—nicotine dependence	1.98e-05	0.000364	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD2—nicotine dependence	1.95e-05	0.000357	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD2—nicotine dependence	1.92e-05	0.000352	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—WASF2—nicotine dependence	1.88e-05	0.000345	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—OPRM1—nicotine dependence	1.86e-05	0.00034	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD2—nicotine dependence	1.82e-05	0.000334	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—WASF1—nicotine dependence	1.81e-05	0.000331	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD2—nicotine dependence	1.77e-05	0.000325	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—WASF2—nicotine dependence	1.67e-05	0.000306	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—OPRM1—nicotine dependence	1.63e-05	0.000298	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—WASF1—nicotine dependence	1.6e-05	0.000293	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2A7—nicotine dependence	1.56e-05	0.000285	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—OPRM1—nicotine dependence	1.44e-05	0.000264	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD2—nicotine dependence	1.43e-05	0.000263	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD2—nicotine dependence	1.34e-05	0.000246	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD2—nicotine dependence	1.18e-05	0.000215	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD2—nicotine dependence	1.04e-05	0.000191	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	9.59e-06	0.000176	CbGpPWpGaD
